Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Targeting CD30 in Patients with Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1561 Accesses

Abstract

The introduction of multi-agent chemotherapy for the treatment of Hodgkin lymphoma is one of the major breakthroughs in clinical oncology. Treatment with multi-agent chemotherapy and improved radiation methods has significantly improved the chance of curing these patients from less than 5 % in 1963 to about 80 % at present. However, there is still a substantial need to improve current treatment approaches particularly for elderly patients or those with relapsed and refractory disease. Cured patients unfortunately are at high risk for late side effects including second malignancies, cardiac toxicity, infertility, and fatigue. Thus, there is a clear need for new and safer drugs that are more selective in targeting the malignant Hodgkin and Reed-Sternberg (HRS) cells in this disease while sparing normal tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bonadonna G, Santoro A (1982) ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9:21–35

    Article  CAS  PubMed  Google Scholar 

  2. De Vita VT, Serpick A (1967) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 8:13

    Google Scholar 

  3. De Vita VT (1981) The consequences of the chemotherapy of Hodgkin’s disease: the 10th David A. Karnofsky memorial lecture. Cancer 47:1–13

    Article  Google Scholar 

  4. Josting A, Muller H, Borchmann P et al (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 28:5074–5080

    Article  PubMed  Google Scholar 

  5. Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117:4208–4217

    Article  CAS  PubMed  Google Scholar 

  6. Moskowitz AJ, Perales MA, Kewalramani T et al (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146:158–163

    Article  PubMed Central  PubMed  Google Scholar 

  7. Ng AK, Bernardo MP, Weller E et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108

    Article  PubMed  Google Scholar 

  8. Specht L (2003) Very long-term follow-up of the Danish National Hodgkin Study Group’s randomized trial of radiotherapy (RT) alone vs. combined modality treatment (CMT) for early stage Hodgkin lymphoma, with special reference to second tumors and overall survival. Blood 102:637A

    Google Scholar 

  9. van Leeuwen FE, Klokman WJ, Veer MB et al (2000) Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 18:487–497

    PubMed  Google Scholar 

  10. Engert A, Burrows F, Jung W et al (1990) Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin’s disease. Cancer Res 50:84–88

    CAS  PubMed  Google Scholar 

  11. Engert A, Martin G, Pfreundschuh M et al (1990) Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab’ fragments on solid human Hodgkin’s disease tumors in mice. Cancer Res 50:2929–2935

    CAS  PubMed  Google Scholar 

  12. Falini B, Flenghi L, Fedeli L et al (1992) In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 82:38–45

    Article  CAS  PubMed  Google Scholar 

  13. Falini B, Bolognesi A, Flenghi L et al (1992) Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195–1196

    Article  CAS  PubMed  Google Scholar 

  14. Schnell R, Staak O, Borchmann P et al (2002) A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res 8:1779–1786

    CAS  PubMed  Google Scholar 

  15. Borchmann P, Schnell R, Fuss I et al (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100:3101–3107

    Article  CAS  PubMed  Google Scholar 

  16. Stein H, Mason DY, Gerdes J et al (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858

    CAS  PubMed  Google Scholar 

  17. Schwab U, Stein H, Gerdes J et al (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299:65–67

    Article  CAS  PubMed  Google Scholar 

  18. Hecht TT, Longo DL, Cossman J et al (1985) Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol 134:4231–4236

    CAS  PubMed  Google Scholar 

  19. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H (1989) BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74:1678–1689

    CAS  PubMed  Google Scholar 

  20. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 68:421–427

    Article  CAS  PubMed  Google Scholar 

  21. Fonatsch C, Latza U, Durkop H, Rieder H, Stein H (1992) Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 14:825–826

    Article  CAS  PubMed  Google Scholar 

  22. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB (1997) Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 17:1535–1542

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Duckett CS, Thompson CB (1997) CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 11:2810–2821

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Mir SS, Richter BW, Duckett CS (2000) Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96:4307–4312

    CAS  PubMed  Google Scholar 

  25. Smith CA, Gruss HJ, Davis T et al (1993) CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349–1360

    Article  CAS  PubMed  Google Scholar 

  26. Younes A, Consoli U, Zhao S et al (1996) CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 93:569–571

    Article  CAS  PubMed  Google Scholar 

  27. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045–2056

    CAS  PubMed  Google Scholar 

  28. Amakawa R, Hakem A, Kundig TM et al (1996) Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice. Cell 84:551–562

    Article  CAS  PubMed  Google Scholar 

  29. DeYoung AL, Duramad O, Winoto A (2000) The TNF receptor family member CD30 is not essential for negative selection. J Immunol 165:6170–6173

    Article  CAS  PubMed  Google Scholar 

  30. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER (1996) Structure and expression of murine CD30 and its role in cytokine production. J Immunol 156:442–449

    CAS  PubMed  Google Scholar 

  31. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR (1999) Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398:341–344

    Article  CAS  PubMed  Google Scholar 

  32. Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ (2005) Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol 174:3891–3896

    Article  CAS  PubMed  Google Scholar 

  33. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C (2001) Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 22:72–77

    Article  CAS  PubMed  Google Scholar 

  34. Sun X, Somada S, Shibata K et al (2008) A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 134:447–458

    Article  CAS  PubMed  Google Scholar 

  35. Sun X, Yamada H, Shibata K et al (2010) CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol 185:7671–7680

    Article  CAS  PubMed  Google Scholar 

  36. Blazar BR, Levy RB, Mak TW et al (2004) CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol 173:2933–2941

    Article  CAS  PubMed  Google Scholar 

  37. Dai Z, Li Q, Wang Y et al (2004) CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 113:310–317

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Bartlett NL, Younes A, Carabasi MH et al (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111:1848–1854

    Article  CAS  PubMed  Google Scholar 

  39. Ansell SM, Horwitz SM, Engert A et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764–2769

    Article  CAS  PubMed  Google Scholar 

  40. Forero-Torres A, Leonard JP, Younes A et al (2009) A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171–179

    Article  CAS  PubMed  Google Scholar 

  41. Duvic M, Reddy SA, Pinter-Brown L et al (2009) A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217–6224

    Article  CAS  PubMed  Google Scholar 

  42. Cerveny CG, Law CL, McCormick RS et al (2005) Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin’s disease cells to conventional chemotherapeutics. Leukemia 19:1648–1655

    Article  CAS  PubMed  Google Scholar 

  43. Blum KA, Jung SH, Johnson JL et al (2010) Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 21:2246–2254

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Lawrence CE, Hammond P, Zalevsky J et al (2007) XmAbTM2513, an Fc engineered humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:2340

    Google Scholar 

  45. Blum KA, Smith M, Fung H et al (2009) Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy. ASCO Annu Meet (Abstr) 27:8531

    Google Scholar 

  46. Hartmann F, Renner C, Jung W et al (2001) Anti-CD16/CD30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7:1873–1881

    CAS  PubMed  Google Scholar 

  47. Zhukovsky E, Achim R, von Tesckow B et al (2013) A phase I study of an anti-CD30 x Anti-CD16A bispecific Tandab antibody, AFM13, in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 122:5116

    Google Scholar 

  48. Schnell R, Dietlein M, Staak JO et al (2005) Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23:4669–4678

    Article  CAS  PubMed  Google Scholar 

  49. Oki Y, Younes A (2012) Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 12:623–632

    Article  CAS  PubMed  Google Scholar 

  50. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res 17:6428–6436

    Article  CAS  PubMed  Google Scholar 

  51. Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465

    Article  CAS  PubMed  Google Scholar 

  52. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Gopal AK, Chen R, Smith SE et al (2013) Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 122(21):4382

    Google Scholar 

  54. Gopal AK, Ramchandren R, O’Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560–568

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196

    Article  CAS  PubMed  Google Scholar 

  56. Jacobsen ED, Advani RH, Oki Y et al (2012) A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results. Blood (ASH Annual Meeting Abstracts) 120

    Google Scholar 

  57. Bartlett NL, Sharman J, Oki Y et al (2013) A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21)

    Google Scholar 

  58. Duvic M, Tetzlaff M, Clos AL et al (2013) Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Blood (ASH Annual Meeting Abstracts) 122(21)

    Google Scholar 

  59. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  CAS  PubMed  Google Scholar 

  60. Fanale MA, Forero-Torres A, Rosenblatt JD et al (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18:248–255

    Article  CAS  PubMed  Google Scholar 

  61. von Geldern G, Pardo CA, Calabresi PA, Newsome SD (2012) PML-IRIS in a patient treated with brentuximab. Neurology 79:2075–2077

    Article  Google Scholar 

  62. Younes A, Connors JM, Park SI et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14:1348–1356

    Article  CAS  PubMed  Google Scholar 

  63. Gopal AK, Bartlett NL, Forero-Torres A et al (2014) Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30+ lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma 55:2328–2334

    Google Scholar 

  64. Evens AM, Hamlin P, Advani RH et al (2013) Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated hodgkin lymphoma (HL): preliminary toxicity findings from a phase II window study Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 98, supplement no. 2:26

    Google Scholar 

  65. Abramson JS, Hochberg E, Joyce R et al (2013) Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin lymphoma: interim analysis of an ongoing phase II trial. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 90, supplement no. 2

    Google Scholar 

  66. Bartlett NL, Chen R, Fanale MA et al (2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7:24

    Article  PubMed Central  PubMed  Google Scholar 

  67. Borchmann P, Eichenauer DA, Pluetschow A et al (2013) Targeted Beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Blood 122:4344

    Google Scholar 

  68. Moskowitz AJ, SH, Gerecitano J et al (2013) PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patient with relapsed and refractory Hodgkin lymphoma. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 98 (2)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Anita Kumar MD

  2. Haematopathology Unit, Bologna University School of Medicine, 40138, Bologna, Italy

    Stefano Pileri

  3. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, USA

    Anas Younes MD

  4. Department of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, 50924, Germany

    Andreas Engert

Authors
  1. Anita Kumar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anas Younes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Engert .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Kumar, A., Pileri, S., Younes, A., Engert, A. (2015). Targeting CD30 in Patients with Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation